Third Swedish National Pension Fund
VC Fund
Stockholm, Sweden
Third Swedish National Pension Fund is a VC fund in Stockholm focused on Biotechnology and Manufacturing. Third Swedish National Pension Fund employs different investment strategies in the interest of spreading risk and protecting pensions for current and future pensioners. The firm was founded in 2001 and is headquartered in Stockholm, Sweden.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Third Swedish National Pension Fund invests in
Stages Third Swedish National Pension Fund invests in
Countries Third Swedish National Pension Fund invests in
Round sizes
Round size
- Post-IPO Equity
- $46M–$85M
- Venture - Series Unknown
- $17M–$2.8B
Investment Focus
Industry
- Biotechnology 4 (57%)
- Manufacturing 3 (43%)
- Health Care 2 (29%)
- Pharmaceutical 2 (29%)
- Apps 1 (14%)
Stage
- Post-IPO Equity 3 (43%)
- Venture - Series Unknown 3 (43%)
- Funding Round 1 (14%)
Country
- Sweden 5 (71%)
- Denmark 1 (14%)
- Ireland 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ITAB Shop Concept
|
ITAB Shop Concept sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The company offers custom-made fitting concepts, innovative solutions for checkout arena and professional lighting systems. | $85.1M / Post-IPO Equity / Sep 25, 2024 | |
Vicore Pharma
|
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $46.2M / Post-IPO Equity / Jun 09, 2023 | |
Northvolt
|
Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan. | $2.8B / Venture - Series Unknown / Jun 09, 2021 | |
Saniona
|
Saniona is a research and development company with low burn rate, a world class team and high ambitions. | $65M / Post-IPO Equity / Aug 10, 2020 | |
Readly
|
Readly is the new way of reading magazines on tablets and smartphones Readly's mission is simple: To be on the cutting edge of the digital magazine revolution. Our expert management team has more than 25 years of experience in the publishing, digital gaming, and broadcasting industries. Readly has headquarters in Sweden. | $16.9M / Venture - Series Unknown / Jun 19, 2019 | |
BONESUPPORT
|
BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life forpatients with bone disorders.BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden. | $36.1M / Venture - Series Unknown / Oct 27, 2016 | |
Strongbridge Biopharma
|
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressingits target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises. | $11M / Oct 30, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Third Swedish National Pension Fund invest in?
Third Swedish National Pension Fund invests primarily in Biotechnology, Manufacturing and Health Care startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Third Swedish National Pension Fund's check size?
Third Swedish National Pension Fund typically joins rounds of $46M–$85M at Post-IPO Equity and $17M–$2.8B at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Third Swedish National Pension Fund participates in.
When did Third Swedish National Pension Fund last invest?
The most recent investment recorded for Third Swedish National Pension Fund closed in Sep 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
